Test Price
14,000 AED✅ Home Collection Available
Oncomine Comprehensive Panel + Tumor Mutation Burden + MSI in UAE | 14,000 AED | DHA Licensed
Executive Summary & Core Metrics
Core Metrics Overview
- Diagnostic Accuracy: 99.9% sensitivity via ISO 9001:2015 accredited next-generation sequencing workflow with orthogonal Sanger confirmation.
- Specimen Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephone-based post-test molecular interpretation by a DHA-licensed specialist provides oncologists with actionable report insights.
- Billing & Insurance: Direct insurance verification via WhatsApp at +971 54 548 8731 prior to sample collection.
Test Overview & Methodology
The Oncomine Comprehensive Panel combined with Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) assessment is a next-generation sequencing (NGS) genomic profiling assay that interrogates hundreds of cancer-related genes using tumor tissue and a matched peripheral blood specimen. This integrated platform simultaneously detects single-nucleotide variants, insertions and deletions, copy number alterations, gene fusions, and two critical immunotherapy biomarkers: TMB and MSI status. The matched normal sample enables somatic versus germline mutation discrimination, providing hereditary risk insight. Our ISO 9001:2015 accredited pipeline includes orthogonal Sanger confirmation for all clinically actionable variants prior to final report generation.
| Feature | Oncomine Comprehensive + TMB + MSI | Single-Gene Panels |
|---|---|---|
| Methodology & Confirmation | NGS with Sanger verification; ISO 9001:2015 accredited | Limited NGS or PCR; no orthogonal confirmation |
| Turnaround Time | 2–3 weeks including clinical interpretation | 4–6 weeks; often lacks integrated biomarker reporting |
| Biomarker Coverage | Full gene panel + TMB + MSI + germline filtering | Targets few genes; no immunotherapy markers |
Physician Insight & Safety Protocols
“As a DHA-licensed specialist in diagnostic radiology, I confirm that the Oncomine Comprehensive Panel provides oncologists with a comprehensive molecular roadmap spanning targetable mutations and immunotherapy determinants. The integrated TMB and MSI analysis is essential for identifying patients likely to benefit from immune checkpoint inhibitors. Genomic data must always be correlated with the patient's complete clinical picture, imaging findings, and emerging resistance patterns. Therapy decisions should never be made based solely on raw genomic outputs without multidisciplinary tumor board review.” – Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Clinical Advisory: Medication Safety Precautions
Patients must continue all prescribed cancer therapies—including targeted agents, immunotherapies, and chemotherapy—without interruption until their treating oncologist reviews the genomic report. The test findings inform future treatment decisions and do not supersede the judgment of the clinical care team. Any modification to medication should occur only under direct medical supervision.
Patient Exclusion Criteria & Emergency Red Flags
- Active uncontrolled infection or coagulopathy at the intended biopsy site warrants medical stabilization before specimen collection.
- Known hypersensitivity to local anesthetics or sedatives used during tissue biopsy necessitates an alternative collection protocol arranged by the referring physician.
- Pregnant individuals may undergo testing only after a formal risk-benefit evaluation and written approval from the treating obstetrician and oncologist.
- Emergency Red Flags: New or worsening pain, hemorrhage, fever, or signs of systemic infection within 48 hours post-biopsy require immediate contact with emergency medical services or the attending oncologist.
Patient FAQ & Clinical Guidance
1. What is the Oncomine Comprehensive Panel + TMB + MSI test used for?
This comprehensive genomic profiling assay simultaneously scans several hundred cancer-associated genes, quantifies tumor mutational burden, and determines microsatellite instability status from a single tumor tissue sample with matched normal blood. It identifies actionable driver mutations, guides targeted therapy selection, predicts immunotherapy response, and distinguishes somatic from germline variants to inform hereditary cancer risk. The test is indicated for patients with advanced or metastatic solid tumors who have exhausted standard treatment options or are seeking personalized oncology approaches.
2. How long do results take and how will I receive them?
The standard turnaround time is 14 to 21 calendar days from the moment the laboratory receives both the tumor tissue and matched blood specimens. You will receive a comprehensive molecular report through our secure patient portal with a notification sent via WhatsApp. The report enumerates all clinically significant variants, TMB score, MSI status, potential therapeutic implications, and relevant clinical trial options. A telephone-based post-test guidance session is provided to help you and your oncologist interpret the findings and determine the next steps in your treatment plan.
3. Do I need a doctor’s prescription for this test?
Yes, a valid prescription from a licensed oncologist or treating physician is mandatory. The prescription must clearly state the clinical indication for comprehensive genomic profiling. Self-referral is not permitted without prior consultation with a DHA-licensed specialist. The prescription ensures that the test is clinically appropriate and that the ordering physician can integrate the results into a comprehensive care plan. The process complies fully with UAE regulatory standards for oncology diagnostics. A prescription is not required for pre-surgical clearance or pregnancy documentation purposes.
4. What type of sample is needed and how is it collected?
The test requires a tumor tissue specimen obtained through a biopsy or surgical resection, plus a matched peripheral blood sample drawn by venipuncture. Tumor tissue can be either a fresh specimen or an archival formalin-fixed paraffin-embedded (FFPE) block. Both samples must be collected within an accredited hospital setting—home phlebotomy is not available due to the invasive nature of tissue acquisition and the strict cold-chain requirements for specimen integrity. The matched blood sample is drawn on the same day or as directed by the laboratory to ensure accurate germline filtering.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
DNA Labs UAE operates under DHA Facility License Number 1143 and strictly adheres to UAE federal data protection and health information governance laws. All genomic data and personal health information are processed, stored, and transmitted in compliance with the following legal instruments:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Governs the collection, processing, and transfer of personal data, including sensitive genetic information, with explicit consent and purpose limitation requirements.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Mandates security standards for electronic health records, data encryption, and audit trails for all digital health transactions.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: Establishes the legal framework for clinical practice standards, patient consent, and professional accountability in diagnostic procedures and result interpretation.
Our laboratory infrastructure maintains ISO 9001:2015 certification, ensuring that every stage from specimen accessioning to report delivery meets international quality benchmarks for clinical genomic testing.
Clinical & Logistical Metadata
| Test Name | Oncomine Comprehensive Panel + Tumor Mutation Burden + Microsatellite Instability |
| Price (AED) | 14,000 AED |
| Turnaround Time | 14–21 calendar days from specimen receipt |
| Sample Type / Matrix | Tumor tissue (FFPE block or fresh biopsy) + Matched peripheral whole blood |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation, ISO 9001:2015 accredited |
| ICD-10-CM Code | C80.1, Z85.9 |
| LOINC Code | 91847-6 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians